OXFORD BIODYNAMICS PLC
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
Results of Annual General Meeting
and
Related Party Transaction
Oxford BioDynamics Plc (AIM: OBD), a revenue-generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry, is pleased to announce that all resolutions as set out in the Notice of Annual General Meeting dated 31 January 2017 were duly passed by shareholders of the Company.
The Company also announces that it has agreed to pay Tessera Investment Management Limited ("Tessera") an additional and final payment of £80,000 in respect of out-of-scope transaction management support services and strategic advice provided to the Company in relation to the Company's recent AIM IPO (the "Transaction"). As disclosed in the Company's Admission Document, published on 1 December 2016, Tessera was initially paid £100,000 for in-scope services rendered during the AIM IPO process.
Katie Long is a director and shareholder of Tessera and became the Company's CFO on 4 October 2016 and is accordingly a related party of the Company under the AIM Rules. The Company's Directors (excluding Katie Long), having consulted with Stifel Nicolaus Europe Limited, the Company's Nominated Adviser, believe that the terms of the Transaction are fair and reasonable insofar as the shareholders of the Company are concerned.
-ENDS-
For further details contact:
Oxford BioDynamics Plc +44 (0)1865 518910
Christian Hoyer Millar, CEO
Katie Long, CFO
FTI Consulting +44 (0)20 3727 1000
Financial Public Relations Advisor
Julia Phillips
Brett Pollard
Natalie Garland-Collins
Matthew Moss
Stifel Nicolaus Europe Limited +44 (0)20 7710 7600
Nominated Advisor and Broker
David Arch
Jonathan Senior
Peter Lees
Ben Maddison
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a revenue‐generating biotechnology company focused on the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.
The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com.
